Physician profile
Mary E Switzer
NPI 1831574003
$2,287.10
in general payments reported to CMS, 2019-2025
24 companies · $271 in 2025
The $271 reported for 2025 was more than what a typical Adult Health (Nurse Practitioner) provider received nationally (typical 2025 total: $182).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $651 · 2022: $429 · 2023: $456 · 2024: $480 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,207.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,206.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $584.85 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $316.31 | 2021-2025 | Rexulti |
| Novartis Pharmaceuticals Corporation | $271.59 | 2021-2023 | |
| Novo Nordisk INC | $195.35 | 2021-2024 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $145.70 | 2024-2025 | |
| Astrazeneca Pharmaceuticals Lp | $124.31 | 2023-2025 | Farxiga, Breztri, Lokelma |
| Glaxosmithkline, LLC. | $118.42 | 2021-2022 | |
| Shield Therapeutics INC | $73.30 | 2023-2025 | Accrufer |
| Lundbeck LLC | $53.86 | 2024-2025 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $52.60 | 2021-2023 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $51.74 | 2021 | |
| Pfizer INC. | $40.43 | 2021-2023 | |
| Sunovion Pharmaceuticals INC. | $37.58 | 2021 | |
| Mylan Specialty L.P. | $29.25 | 2021-2023 | Yupelri |
| Neurocrine Biosciences, INC. | $27.87 | 2025 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $24.93 | 2025 | Caplyta |
| Genentech USA, INC. | $22.56 | 2021 | |
| Dexcom, INC. | $19.75 | 2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $19.67 | 2023 | Gemtesa |
| Astellas Pharma US INC | $16.63 | 2023 | Myrbetriq |
| Lilly USA, LLC | $16.52 | 2022 | |
| Exact Sciences Corporation | $16.04 | 2025 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $15.30 | 2021 | |
| Merck Sharp & Dohme LLC | $12.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Switzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.